blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3288945

EP3288945 - IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.07.2020
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  16.08.2019
FormerGrant of patent is intended
Status updated on  11.12.2018
FormerRequest for examination was made
Status updated on  02.02.2018
FormerThe international publication has been made
Status updated on  04.11.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse / BE
[2018/10]
Inventor(s)01 / SAVALL, Bradley M.
3210 Merryfield Row
San Diego, California 92121 / US
02 / SWANSON, Devin M.
3210 Merryfield Row
San Diego, California 92121 / US
03 / WU, Dongpei
3210 Merryfield Row
San Diego, California 92121 / US
04 / AMERIKS, Michael K.
3210 Merryfield Row
San Diego, California 92121 / US
 [2018/10]
Representative(s)McGuire, Gillian Margaret
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2018/10]
Application number, filing date16721038.428.04.2016
[2018/10]
WO2016US29791
Priority number, dateUS201562154310P29.04.2015         Original published format: US 201562154310 P
[2018/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016176457
Date:03.11.2016
Language:EN
[2016/44]
Type: A1 Application with search report 
No.:EP3288945
Date:07.03.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 03.11.2016 takes the place of the publication of the European patent application.
[2018/10]
Type: B1 Patent specification 
No.:EP3288945
Date:18.09.2019
Language:EN
[2019/38]
Search report(s)International search report - published on:EP03.11.2016
ClassificationIPC:C07D487/04, A61K31/4985, A61K31/519, A61P25/00
[2018/10]
CPC:
C07D487/04 (EP,KR,US); A61K31/4985 (KR); A61K31/519 (KR);
A61P25/00 (EP,US); C07D231/54 (EP,US); C07D235/04 (EP,US);
C07D239/80 (EP,US); C07D249/18 (EP,US); C07D275/06 (EP,US);
C07D277/62 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/10]
Extension statesBA20.10.2017
ME20.10.2017
Validation statesMA20.10.2017
MD20.10.2017
TitleGerman:IMIDAZOPYRAZINE UND PYRAZOLOPYRIMIDINE UND IHRE VERWENDUNG ALS AMPA-REZEPTORMODULATOREN[2018/10]
English:IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS[2018/10]
French:IMIDAZOPYRAZINES ET PYRAZOLOPYRIMIDINES ET LEUR UTILISATION COMME MODULATEURS DES RÉCEPTEURS AMPA[2018/10]
Entry into regional phase20.10.2017National basic fee paid 
20.10.2017Designation fee(s) paid 
20.10.2017Examination fee paid 
Examination procedure20.10.2017Examination requested  [2018/10]
20.10.2017Date on which the examining division has become responsible
21.06.2018Amendment by applicant (claims and/or description)
12.12.2018Communication of intention to grant the patent
29.05.2019Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
08.08.2019Fee for grant paid
08.08.2019Fee for publishing/printing paid
08.08.2019Receipt of the translation of the claim(s)
Opposition(s)19.06.2020No opposition filed within time limit [2020/35]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
08.08.2019Request for further processing filed
08.08.2019Full payment received (date of receipt of payment)
Request granted
21.08.2019Decision despatched
Fees paidRenewal fee
11.04.2018Renewal fee patent year 03
15.04.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU28.04.2016
AL18.09.2019
AT18.09.2019
CY18.09.2019
CZ18.09.2019
DK18.09.2019
EE18.09.2019
FI18.09.2019
HR18.09.2019
IT18.09.2019
LT18.09.2019
LV18.09.2019
MC18.09.2019
MK18.09.2019
MT18.09.2019
NL18.09.2019
PL18.09.2019
RO18.09.2019
RS18.09.2019
SE18.09.2019
SI18.09.2019
SK18.09.2019
SM18.09.2019
TR18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
IS19.01.2020
PT20.01.2020
LU28.04.2020
CH30.04.2020
LI30.04.2020
[2022/32]
Former [2022/27]HU28.04.2016
AL18.09.2019
AT18.09.2019
CY18.09.2019
CZ18.09.2019
DK18.09.2019
EE18.09.2019
FI18.09.2019
HR18.09.2019
IT18.09.2019
LT18.09.2019
LV18.09.2019
MC18.09.2019
MT18.09.2019
NL18.09.2019
PL18.09.2019
RO18.09.2019
RS18.09.2019
SE18.09.2019
SI18.09.2019
SK18.09.2019
SM18.09.2019
TR18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
IS19.01.2020
PT20.01.2020
LU28.04.2020
CH30.04.2020
LI30.04.2020
Former [2021/08]AL18.09.2019
AT18.09.2019
CZ18.09.2019
DK18.09.2019
EE18.09.2019
FI18.09.2019
HR18.09.2019
IT18.09.2019
LT18.09.2019
LV18.09.2019
MC18.09.2019
NL18.09.2019
PL18.09.2019
RO18.09.2019
RS18.09.2019
SE18.09.2019
SI18.09.2019
SK18.09.2019
SM18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
IS19.01.2020
PT20.01.2020
LU28.04.2020
CH30.04.2020
LI30.04.2020
Former [2020/52]AL18.09.2019
AT18.09.2019
CZ18.09.2019
DK18.09.2019
EE18.09.2019
FI18.09.2019
HR18.09.2019
IT18.09.2019
LT18.09.2019
LV18.09.2019
MC18.09.2019
NL18.09.2019
PL18.09.2019
RO18.09.2019
RS18.09.2019
SE18.09.2019
SI18.09.2019
SK18.09.2019
SM18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
IS19.01.2020
PT20.01.2020
Former [2020/37]AL18.09.2019
AT18.09.2019
CZ18.09.2019
DK18.09.2019
EE18.09.2019
FI18.09.2019
HR18.09.2019
IT18.09.2019
LT18.09.2019
LV18.09.2019
NL18.09.2019
PL18.09.2019
RO18.09.2019
RS18.09.2019
SE18.09.2019
SI18.09.2019
SK18.09.2019
SM18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
IS19.01.2020
PT20.01.2020
Former [2020/36]AL18.09.2019
AT18.09.2019
CZ18.09.2019
DK18.09.2019
EE18.09.2019
FI18.09.2019
HR18.09.2019
IT18.09.2019
LT18.09.2019
LV18.09.2019
NL18.09.2019
PL18.09.2019
RO18.09.2019
RS18.09.2019
SE18.09.2019
SK18.09.2019
SM18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
IS19.01.2020
PT20.01.2020
Former [2020/27]AL18.09.2019
AT18.09.2019
CZ18.09.2019
EE18.09.2019
FI18.09.2019
HR18.09.2019
IT18.09.2019
LT18.09.2019
LV18.09.2019
NL18.09.2019
PL18.09.2019
RO18.09.2019
RS18.09.2019
SE18.09.2019
SK18.09.2019
SM18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
PT20.01.2020
IS24.02.2020
Former [2020/25]AL18.09.2019
AT18.09.2019
CZ18.09.2019
EE18.09.2019
FI18.09.2019
HR18.09.2019
IT18.09.2019
LT18.09.2019
LV18.09.2019
NL18.09.2019
PL18.09.2019
RO18.09.2019
RS18.09.2019
SE18.09.2019
SK18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
PT20.01.2020
IS24.02.2020
Former [2020/24]AL18.09.2019
AT18.09.2019
EE18.09.2019
FI18.09.2019
HR18.09.2019
IT18.09.2019
LT18.09.2019
LV18.09.2019
NL18.09.2019
PL18.09.2019
RO18.09.2019
RS18.09.2019
SE18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
PT20.01.2020
IS24.02.2020
Former [2020/23]AL18.09.2019
AT18.09.2019
EE18.09.2019
FI18.09.2019
HR18.09.2019
IT18.09.2019
LT18.09.2019
LV18.09.2019
NL18.09.2019
PL18.09.2019
RO18.09.2019
RS18.09.2019
SE18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
PT20.01.2020
Former [2020/22]AL18.09.2019
EE18.09.2019
FI18.09.2019
HR18.09.2019
LT18.09.2019
LV18.09.2019
NL18.09.2019
RS18.09.2019
SE18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
PT20.01.2020
Former [2020/20]AL18.09.2019
FI18.09.2019
HR18.09.2019
LT18.09.2019
LV18.09.2019
NL18.09.2019
RS18.09.2019
SE18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
Former [2020/15]AL18.09.2019
FI18.09.2019
HR18.09.2019
LT18.09.2019
LV18.09.2019
RS18.09.2019
SE18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
Former [2020/12]FI18.09.2019
HR18.09.2019
LT18.09.2019
LV18.09.2019
RS18.09.2019
SE18.09.2019
BG18.12.2019
NO18.12.2019
GR19.12.2019
Former [2020/10]FI18.09.2019
LT18.09.2019
SE18.09.2019
BG18.12.2019
NO18.12.2019
Former [2020/09]FI18.09.2019
LT18.09.2019
NO18.12.2019
Former [2020/08]LT18.09.2019
NO18.12.2019
Cited inInternational search[A]WO2008053031  (GLAXO GROUP LTD [GB], et al) [A] 1-39 * page 20, lines 21-27; claims 1,14 *;
 [A]WO2008113795  (GLAXO GROUP LTD [GB], et al) [A] 1-39 * page 20, lines 29-32; example 40; claims 1,4 *;
 [A]WO2008148832  (GLAXO GROUP LTD [GB], et al) [A] 1-39 * page 17, lines 12-15; examples 20,21; claims 1, 8 *;
 [A]WO2010066658  (GLAXO GROUP LTD [GB], et al) [A] 1-39 * page 9, lines 21-25; example 5; claims 1, 8 *;
 [A]  - B. PIROTTE, P. FRANCOTTE, E. GOFFIN, P.DE TULLIO, "AMPA receptor positive allosteric modulators: a patent review", EXPERT OPINION THERAPEUTIC PATENTS, (2013), vol. 23, no. 5, pages 615 - 628, XP009190352 [A] 1-39 * figures 1-13 *
by applicantWO0001376
    - GILL; BREDT, NEUROPSYCHOPHARMACOLOGY, (2011), vol. 36, no. 1, pages 362 - 363
    - MICHAEL A.; ROGAWSKI, "Revisiting AMPA Receptors as an AntiEpileptic Drug Target", EPILEPSY CURRENTS, (2011), vol. 11.2
    - SMALL ET AL., NAT. REV. NEUROSCI., (2011), vol. 12, pages 585 - 601
    - HARRISON, BRAIN, (2002), vol. 125, pages 1428 - 1449
    - CHEN ET AL., BIPOLAR DISORD., (2011), vol. 13, pages 1 - 15
    - DU ET AL., J NEUROSCI, (2008), vol. 28, pages 68 - 79
    - NOLEN; BLOEMKOLK, NEUROPSYCHOBIOLOGY, (2000), vol. 42, no. 1
    - DU ET AL., J NEUROSCI, (2004), vol. 24, pages 6578 - 6589
    - ENGIN; TREIT, BEHAV PHARMACOL, (2007), vol. 18, pages 365 - 374
    - MCNAUGHTON ET AL., BEHAV PHARMACOL, (2007), vol. 18, pages 329 - 346
    - YEUNG ET AL., HIPPOCAMPUS, (2013), vol. 23, pages 278 - 286
    - YEUNG ET AL., NEUROPHARMACOLOGY, (2012), vol. 62, pages 155 - 160
    - HECKERS; KONRADI, CURR TOP BEHAV NEUROSCI., (2010), vol. 4, pages 529 - 553
    - TREGELLAS ET AL., AM J PSYCHIATRY, (2014), vol. 171, pages 549 - 556
    - SCHOBEL, ARCH GEN PSYCH, (2009), vol. 66, pages 938 - 946
    - Van Nostrand's Encyclopedia of Chemistry, (2005), page 261
    - G.S. PAULEKUHN ET AL., "Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database", J. MED. CHEM., (2007), vol. 50, doi:doi:10.1021/jm701032y, pages 6665 - 72, XP002651069

DOI:   http://dx.doi.org/10.1021/jm701032y
    - S.M. BERGE ET AL., "Pharmaceutical Salts", J PHARM SCI., (1977), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - FLEISHER ET AL., ADV. DRUG DELIVERY REV., (1996), vol. 19, pages 115 - 130
    - ROBINSON ET AL., J MED CHEM., (1996), vol. 39, no. 1, pages 10 - 18
    - BERTOLINI ET AL., J MED CHEM., (1997), vol. 40, pages 2011 - 2016
    - SHAN ET AL., J PHARM SCI, (1997), vol. 86, no. 7, pages 765 - 767
    - BAGSHAWE, DRUG DEV RES., (1995), vol. 34, pages 220 - 230
    - BODOR, ADV DRUG RES., (1984), vol. 13, pages 224 - 331
    - KAMBE, TOHRU; CORREIA, BRUNO E.; NIPHAKIS, MICAH J.; CRAVATT, BENJAMIN F., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (2014), vol. 136, no. 30, pages 10777 - 10782
    - STRANGE ET AL., "Functional characterisation of homomeric ionotropic glutamate receptors GluR1-GluR6 in a fluorescence-based high throughput screening assay", COMB CHEM HIGH THROUGHPUT SCREEN, (2006), vol. 9, no. 2, pages 147 - 158
    - CHO ET AL., "Two families of TARP isoforms that have distinct effects on the kinetic properties of AMPA receptors and synaptic currents", NEURON, (2007), vol. 55, no. 6, pages 890 - 904
    - SHI ET AL., "The stoichiometry of AMPA receptors and TARPs varies by neuronal cell type", NEURON, (2009), vol. 62, no. 5, pages 633 - 640
    - LAZZARO ET AL., "Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist", NEUROPHARMACOLOGY, (2002), vol. 42, no. 2, pages 143 - 153, XP027251994
    - TOMITA ET AL., "Functional studies and distribution define a family of transmembrane AMPA receptor regulatory proteins", J CELL BIOL, (2003), vol. 161, no. 4, pages 805 - 816
    - BREWER, G. J., "Isolation and culture of adult rat hippocampal neurons", JOURNAL OF NEUROSCIENCE METHODS, (1997), vol. 71, no. 2, pages 143 - 155
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.